# Assessment of Delayed-type Hypersensitivity Reactions to SARS-CoV-2 Peptide Antigens

> **NCT05216510** · PHASE1 · TERMINATED · sponsor: **Tonix Pharmaceuticals, Inc.** · enrollment: 9 (actual)

## Conditions studied

- Detection of Delayed-type Hypersensitivity Reactions to SARS-CoV-2 in Individuals Exposed to SARS-CoV-2

## Interventions

- **BIOLOGICAL:** TNX-2110
- **BIOLOGICAL:** TNX-2120
- **BIOLOGICAL:** TNX-2130
- **BIOLOGICAL:** CANDIN
- **BIOLOGICAL:** Diluent

## Key facts

- **NCT ID:** NCT05216510
- **Lead sponsor:** Tonix Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-01-07
- **Primary completion:** 2022-09-17
- **Final completion:** 2022-09-17
- **Target enrollment:** 9 (ACTUAL)
- **Why stopped:** Lack of efficacy
- **Last updated:** 2024-11-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05216510

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05216510, "Assessment of Delayed-type Hypersensitivity Reactions to SARS-CoV-2 Peptide Antigens". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05216510. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*